<?xml version="1.0" encoding="UTF-8"?>
<p id="para0006">Direct oral anticoagulants (DOACs) are favored due to their oral administration, selective coagulation factor inhibition, lack of required blood monitoring, and safety profile relative to vitamin K antagonists.
 <xref rid="bib0027" ref-type="bibr">
  <sup>27</sup>
 </xref> Early observations of lower than expected mortality in subjects on DOACS with chronic atrial fibrillation who contract COVID-19 suggested that anticoagulation may benefit patients with COVID-19 in the prehospital setting.
 <xref rid="bib0010" ref-type="bibr">
  <sup>10</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib0028" ref-type="bibr">
  <sup>28</sup>
 </xref> DOACs may be a preferred choice over other anticoagulant options for post-hospital discharge from COVID-19 with other indications for therapeutic thromboprophylaxis.
 <xref rid="bib0027" ref-type="bibr">
  <sup>27</sup>
 </xref>
</p>
